Flagship Pioneering formed Etcelera, a new company that takes the Cellarity AI drug discovery platform forward alongside the platforms of Etiome and Empress Therapeutics. Cellarity itself continues only as a standalone clinical company built around its sickle cell candidate CLY-124, with the platform no longer part of it.
Our readBuyers and partners evaluating the Cellarity platform now deal with Etcelera, so the vendor listed in the index no longer owns the AI platform the index grades.